BlackThorn Therapeutics

25 articles about BlackThorn Therapeutics

• 

  Clinical Catch-Up: Jan 20-24

  1/27/2020

  The week after the JP Morgan Healthcare Conference tends to be slower than the week of, and last week was no outlier. Still, there were clinical trial updates. Here’s a look.

• BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders

  1/23/2020

  BlackThorn Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing targeted medicines to treat central nervous system (CNS) disorders, today announced the advancement of Phase 2 clinical development for its lead drug candidate, BTRX-335140 (BTRX-140), a selective antagonist for the kappa opioid receptor (KOR)

• BlackThorn Therapeutics Reports Data Supporting Phase 2 Development of KOR Antagonist, BTRX-335140, in Depression and Other CNS Disorders

  12/11/2019

  PET study of BTRX-335140 confirms KOR target engagement in the brain

• BlackThorn Therapeutics Reports New Insights into Neurobehavioral Disorders at the 49th Annual Meeting of the Society for Neuroscience

  10/23/2019

  BlackThorn Therapeutics, Inc., announced that the company presented new data science research into the underlying biology of neurobehavioral disorders at the 49th annual meeting of the Society for Neuroscience taking place October 19-23 in Chicago.

• BlackThorn Therapeutics Appoints William J. Martin, Ph.D., as Chief Executive Officer to Lead Next Stage of Growth

  10/21/2019

  Dr. Martin has previously served as the company’s president and chief operating officer, as well as its chief scientific officer.

• BlackThorn Therapeutics Appoints Healthcare Technology Innovator, Monique Levy, as Chief Strategy Officer

  9/9/2019

  BlackThorn Therapeutics, Inc., a clinical-stage, neurobehavioral health company pioneering next-generation artificial intelligence (AI) technologies to advance targeted therapeutics, today announced the appointment of Monique Levy as chief strategy officer.

• BlackThorn Therapeutics Announces Its Participation in the Reward Task Optimization Consortium (RTOC)

  7/22/2019

  Focus on clinical tool development to advance new treatments for neurobehavioral disorders

• P1vital announces launch of the Reward Task Optimisation Consortium - RTOC

  7/22/2019

  Research partners from pharma, academia, and SMEs have come together to form the Reward Task Optimisation Consortium.

• BlackThorn Therapeutics Closes $76 Million Series B to Advance Targeted Therapeutics for Mental Health

  6/13/2019

  Company Also Expands Board of Directors and Executive Management Team with Key Appointments

• 

  BlackThorn Raises $76 Million to Advance Drugs for Neurobehavioral Disorders

  6/13/2019

  With Backing from Google, J&J and Others, BlackThorn Raises $76 Million Series B.

• BlackThorn Therapeutics Announces Positive Phase 1 Results for Its Selective KOR Antagonist, BTRX-335140

  4/1/2019

  Phase 1 results and new translational data supporting the development of BTRX-335140 for neurobehavioral disorders presented at the Kappa Therapeutics 2019 Conference

• BlackThorn Therapeutics Names Bill Martin, Ph.D., President and Chief Operating Officer

  11/5/2018

  Paul L. Berns Joins Board of Directors as Executive Chair

• BlackThorn Therapeutics Announces Exclusive Licensing Agreement and Extension of Key Collaboration With Yale University

  8/6/2018

  First Publication Emerges from Company’s Multi-year Research Collaboration with Yale’s Division of Neurocognition, Neurocomputation, and Neurogenetics

• BlackThorn Therapeutics Names George S. Golumbeski, Ph.D., to Board of Directors

  6/12/2018

  BlackThorn Therapeutics today announced the appointment of a key strategic executive to the company’s board of directors, George S. Golumbeski, Ph.D.

• BlackThorn Therapeutics Initiates Phase 1 Study of BTRX-335140, an Investigational Kappa Opioid Receptor (KOR) Antagonist

  6/6/2018

  Selective KOR Antagonist Represents BlackThorn’s Second Molecule to Enter Clinic

• 

  A Look at A Few Hot New Approaches and News in the Research Imaging Market

  6/1/2018

  Advances in data storage and processing, as well as biomarker identification, has led to cutting-edge breakthroughs in clinical and research imaging technology.  Here’s a look at just a few of these stories.

• BlackThorn Therapeutics Presents Preclinical and Clinical Data From Its First-in-Class NOPR Antagonist at American College of Neuropsychopharmacology Annual Meeting

  12/7/2017

  Preclinical study results also showed that NOPR antagonism improved motor symptoms in a non-human primate model of Parkinson’s disease.

• BlackThorn Therapeutics Names Matthew K. Fust To Board Of Directors

  8/1/2017

• BlackThorn Therapeutics Enrolls First Patient In Phase IIa Study Of Lead Compound, BTRX-246040, In Major Depressive Disorder

  7/24/2017

• BlackThorn Therapeutics To Receive Up To $8 Million In NIH Blueprint Neurotherapeutics Network Funding To Advance Kappa Opioid Receptor (KOR) Antagonist Program

  6/20/2017